Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Dehbi HM, et al. Among authors: hackshaw a. Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51. doi: 10.1016/S2213-8587(18)30306-1. Epub 2018 Nov 27. Lancet Diabetes Endocrinol. 2019. PMID: 30501974 Free PMC article. Clinical Trial.
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Mallick U, et al. Among authors: hackshaw a. N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589. N Engl J Med. 2012. PMID: 22551128 Free article. Clinical Trial.
Well-being after radiation therapy in thyroid cancer.
Hackshaw A, Kadalayil L, Mallick U. Hackshaw A, et al. N Engl J Med. 2013 Feb 14;368(7):685-6. doi: 10.1056/NEJMc1212592. N Engl J Med. 2013. PMID: 23406048 No abstract available.
Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin.
Watkins RJ, Imruetaicharoenchoke W, Read ML, Sharma N, Poole VL, Gentilin E, Bansal S, Bosseboeuf E, Fletcher R, Nieto HR, Mallick U, Hackshaw A, Mehanna H, Boelaert K, Smith VE, McCabe CJ. Watkins RJ, et al. Among authors: hackshaw a. J Clin Endocrinol Metab. 2016 Dec;101(12):4551-4563. doi: 10.1210/jc.2016-1932. Epub 2016 Sep 7. J Clin Endocrinol Metab. 2016. PMID: 27603901 Free PMC article.
Investigating Subgroup Effects in Randomized Clinical Trials.
Dehbi HM, Hackshaw A. Dehbi HM, et al. Among authors: hackshaw a. J Clin Oncol. 2017 Jan 10;35(2):253-254. doi: 10.1200/JCO.2016.70.2217. Epub 2016 Oct 31. J Clin Oncol. 2017. PMID: 28056207 Review. No abstract available.
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L; ACT II study group. Glynne-Jones R, et al. Among authors: hackshaw a. Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11. Lancet Oncol. 2017. PMID: 28209296 Free PMC article. Clinical Trial.
258 results